Business & Finance
Business and Finance
Business and Finance 
Thu, May 6, 2010
AmbiCom Names Louis Wong, Industry Veteran, as Advisor to the Company
SAN JOSE, CA--(Marketwire - May 6, 2010) - AmbiCom Holdings, Inc. (
The announcement was made by John Hwang, Chief Executive Officer of AmbiCom, who said: "We are very pleased that Dr. Wong has agreed to become an advisor to the company. His more than a decade of experience in developing and marketing new medical technologies will be particularly valuable as we continue our growth."
Dr. Wong has more than 17 years of integrated circuit and sensor experience in medical and consumer products. He was responsible for bringing more than 50 successful products to market in the consumer, medical, industrial and military fields. In addition to developing the IC for the world's first totally implantable cochlear implant while a senior integrated circuit designer at Cochlear in 1997-2000, he also developed and architected new lines of pacemakers and defibrillators while a chief IC designer at St. Jude Medical, from 2000 to 2006. From 2006 to the present time, he has been the Chief Executive and Chief Technology Officer of a privately-held company working on analog and sensor products.
Dr. Wong has been a part time instructor at San Jose State University and a past IEEE Solid State Society Silicon-Valley Chapter Officer. He completed his Ph.D. in low-power analog IC design in 1997 from the University of New South Wales in Australia and his Bachelors of Engineering with First Class Honors from the University of Adelaide, also in Australia.
About AmbiCom
AmbiCom is headquartered in San Jose, California, and is a leading designer and developer of wireless products focusing on the wireless medical industry. The Company's wireless modules and devices are based on the Company's innovative application software for both Wi-Fi and Bluetooth technologies. AmbiCom is committed to wireless design and development of software and hardware, and to bringing new and innovative products to the wireless medical markets and other sectors. The Company plans to grow organically, and to augment that growth by selectively acquiring complementary products and technologies via acquisition opportunities deemed to be of strategic value.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements including, but not limited to, our ability to maintain our website and associated computer systems, our ability to generate sufficient market acceptance for our products and services, our inability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by use in our reports filed with the U.S. Securities & Exchange Commission, which advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.